[1]
Maxwell V,Shulkes A,Brown JC,Solomon TE,Walsh JH,Grossman MI, Effect of gastric inhibitory polypeptide on pentagastrin-stimulated acid secretion in man. Digestive diseases and sciences. 1980 Feb;
[PubMed PMID: 7353457]
[2]
Dupre J,Ross SA,Watson D,Brown JC, Stimulation of insulin secretion by gastric inhibitory polypeptide in man. The Journal of clinical endocrinology and metabolism. 1973 Nov;
[PubMed PMID: 4749457]
[3]
Kuhre RE, Wewer Albrechtsen NJ, Hartmann B, Deacon CF, Holst JJ. Measurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. Journal of diabetes and its complications. 2015 Apr:29(3):445-50. doi: 10.1016/j.jdiacomp.2014.12.006. Epub 2014 Dec 15
[PubMed PMID: 25623632]
[4]
Scheen AJ. Pharmacological management of type 2 diabetes: what's new in 2017? Expert review of clinical pharmacology. 2017 Dec:10(12):1383-1394. doi: 10.1080/17512433.2017.1376652. Epub 2017 Sep 11
[PubMed PMID: 28879786]
[5]
Wyncott D,Lyon C,Mounsey A, PURLs: Need an add-on to metformin? Consider this. The Journal of family practice. 2017 Jan;
[PubMed PMID: 28188318]
[6]
Fehmann HC, Göke R, Göke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocrine reviews. 1995 Jun:16(3):390-410
[PubMed PMID: 7671853]
[7]
Holst JJ, On the physiology of GIP and GLP-1. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2004 Nov-Dec;
[PubMed PMID: 15655703]
[8]
Takeda J,Seino Y,Tanaka K,Fukumoto H,Kayano T,Takahashi H,Mitani T,Kurono M,Suzuki T,Tobe T, Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor. Proceedings of the National Academy of Sciences of the United States of America. 1987 Oct;
[PubMed PMID: 2890159]
[9]
Villar HV,Fender HR,Rayford PL,Bloom SR,Ramus NI,Thompson JC, Suppression of gastrin release and gastric secretion by gastric inhibitory polypeptide (GIP) and vasoactive intestinal polypeptide (VIP). Annals of surgery. 1976 Jul;
[PubMed PMID: 938120]
[10]
Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology. 1993 Dec:133(6):2861-70
[PubMed PMID: 8243312]
[11]
Deacon CF, Nauck MA, Meier J, Hücking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. The Journal of clinical endocrinology and metabolism. 2000 Oct:85(10):3575-81
[PubMed PMID: 11061504]
[12]
O'Dorisio TM,Sirinek KR,Mazzaferri EL,Cataland S, Renal effects on serum gastric inhibitory polypeptide (GIP). Metabolism: clinical and experimental. 1977 Jun;
[PubMed PMID: 870794]
[14]
Irwin N, Gault V, Flatt PR. Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease? Expert opinion on investigational drugs. 2010 Sep:19(9):1039-48. doi: 10.1517/13543784.2010.513381. Epub
[PubMed PMID: 20698813]
Level 3 (low-level) evidence
[15]
Martin B, Lopez de Maturana R, Brenneman R, Walent T, Mattson MP, Maudsley S. Class II G protein-coupled receptors and their ligands in neuronal function and protection. Neuromolecular medicine. 2005:7(1-2):3-36
[PubMed PMID: 16052036]
[16]
Mayo KE,Miller LJ,Bataille D,Dalle S,Göke B,Thorens B,Drucker DJ, International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacological reviews. 2003 Mar;
[PubMed PMID: 12615957]
[17]
Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best practice & research. Clinical endocrinology & metabolism. 2009 Aug:23(4):479-86. doi: 10.1016/j.beem.2009.03.004. Epub
[PubMed PMID: 19748065]
[18]
Hinke SA, Gelling RW, Pederson RA, Manhart S, Nian C, Demuth HU, McIntosh CH. Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes. 2002 Mar:51(3):652-61
[PubMed PMID: 11872663]
[19]
Deacon CF,Plamboeck A,Rosenkilde MM,de Heer J,Holst JJ, GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations. American journal of physiology. Endocrinology and metabolism. 2006 Sep;
[PubMed PMID: 16608883]
[21]
Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986 Jan:29(1):46-52
[PubMed PMID: 3514343]
[22]
Reznik Y, Allali-Zerah V, Chayvialle JA, Leroyer R, Leymarie P, Travert G, Lebrethon MC, Budi I, Balliere AM, Mahoudeau J. Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. The New England journal of medicine. 1992 Oct 1:327(14):981-6
[PubMed PMID: 1325609]
[24]
Scheen AJ. Cardiovascular effects of gliptins. Nature reviews. Cardiology. 2013 Feb:10(2):73-84. doi: 10.1038/nrcardio.2012.183. Epub 2013 Jan 8
[PubMed PMID: 23296071]
[25]
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. The New England journal of medicine. 2013 Oct 3:369(14):1317-26. doi: 10.1056/NEJMoa1307684. Epub 2013 Sep 2
[PubMed PMID: 23992601]
[26]
Xiong SW,Cao J,Liu XM,Deng XM,Liu Z,Zhang FT, Effect of Modified Roux-en-Y Gastric Bypass Surgery on GLP-1, GIP in Patients with Type 2 Diabetes Mellitus. Gastroenterology research and practice. 2015;
[PubMed PMID: 26167177]